Literature DB >> 22105825

Reporting of adjuvant breast cancer trials: when is the right time?

Helena M Earl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22105825      PMCID： PMC3255558          DOI： 10.1200/JCO.2011.38.2747

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Riikka Huovinen; Arja Jukkola-Vuorinen; Minna Tanner; Riitta Kokko; Johan Ahlgren; Päivi Auvinen; Outi Paija; Leena Helle; Kenneth Villman; Paul Nyandoto; Greger Nilsson; Marjo Pajunen; Raija Asola; Paula Poikonen; Mika Leinonen; Vesa Kataja; Petri Bono; Henrik Lindman
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

2.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

3.  Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer.

Authors:  W M Gregory; K Bolland; J Whitehead; R L Souhami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

Authors:  Christopher J Poole; Helena M Earl; Louise Hiller; Janet A Dunn; Sarah Bathers; Robert J Grieve; David A Spooner; Rajiv K Agrawal; Indrajit N Fernando; A Murray Brunt; Susan M O'Reilly; S Michael Crawford; Daniel W Rea; Peter Simmonds; Janine L Mansi; Andrew Stanley; Peter Harvey; Karen McAdam; Liz Foster; Robert C F Leonard; Christopher J Twelves
Journal:  N Engl J Med       Date:  2006-11-02       Impact factor: 91.245

5.  Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Riikka Huovinen; Arja Jukkola-Vuorinen; Minna Tanner; Raija Asola; Riitta Kokko; Johan Ahlgren; Päivi Auvinen; Akseli Hemminki; Outi Paija; Leena Helle; Lauri Nuortio; Kenneth Villman; Greger Nilsson; Sirpa-Liisa Lahtela; Kaisa Lehtiö; Marjo Pajunen; Paula Poikonen; Paul Nyandoto; Vesa Kataja; Petri Bono; Mika Leinonen; Henrik Lindman
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

6.  Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Authors:  Fiona M Blows; Kristy E Driver; Marjanka K Schmidt; Annegien Broeks; Flora E van Leeuwen; Jelle Wesseling; Maggie C Cheang; Karen Gelmon; Torsten O Nielsen; Carl Blomqvist; Päivi Heikkilä; Tuomas Heikkinen; Heli Nevanlinna; Lars A Akslen; Louis R Bégin; William D Foulkes; Fergus J Couch; Xianshu Wang; Vicky Cafourek; Janet E Olson; Laura Baglietto; Graham G Giles; Gianluca Severi; Catriona A McLean; Melissa C Southey; Emad Rakha; Andrew R Green; Ian O Ellis; Mark E Sherman; Jolanta Lissowska; William F Anderson; Angela Cox; Simon S Cross; Malcolm W R Reed; Elena Provenzano; Sarah-Jane Dawson; Alison M Dunning; Manjeet Humphreys; Douglas F Easton; Montserrat García-Closas; Carlos Caldas; Paul D Pharoah; David Huntsman
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069
  6 in total
  1 in total

1.  Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?

Authors:  Helena Earl; Elena Provenzano; Jean Abraham; Janet Dunn; Anne-Laure Vallier; Ioannis Gounaris; Louise Hiller
Journal:  BMC Med       Date:  2015-09-22       Impact factor: 8.775
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.